Deutsche Bank AG trimmed its stake in Glaukos Corporation (NYSE:GKOS – Free Report) by 8.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,936 shares of the medical instruments supplier’s stock after selling 3,923 shares during the quarter. Deutsche Bank AG owned 0.07% of Glaukos worth $3,931,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in GKOS. Bessemer Group Inc. grew its holdings in Glaukos by 133.9% during the first quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 158 shares during the last quarter. Whipplewood Advisors LLC raised its holdings in shares of Glaukos by 3,957.1% in the first quarter. Whipplewood Advisors LLC now owns 284 shares of the medical instruments supplier’s stock valued at $28,000 after buying an additional 277 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Glaukos by 72.9% in the first quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock valued at $37,000 after buying an additional 159 shares during the last quarter. Versant Capital Management Inc increased its position in Glaukos by 583.9% in the first quarter. Versant Capital Management Inc now owns 383 shares of the medical instruments supplier’s stock worth $38,000 after purchasing an additional 327 shares during the period. Finally, CoreCap Advisors LLC increased its position in Glaukos by 36.4% in the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 200 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.
Glaukos Stock Performance
Shares of Glaukos stock opened at $89.47 on Tuesday. The business’s fifty day simple moving average is $96.74 and its 200 day simple moving average is $102.50. The firm has a market capitalization of $5.13 billion, a P/E ratio of -54.22 and a beta of 0.78. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71. The company has a current ratio of 5.51, a quick ratio of 4.69 and a debt-to-equity ratio of 0.09.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on the company. Truist Financial reiterated a “buy” rating and set a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a report on Thursday, May 1st. Mizuho set a $130.00 target price on Glaukos in a research note on Thursday, July 31st. Stifel Nicolaus dropped their price objective on Glaukos from $140.00 to $115.00 and set a “buy” rating on the stock in a research note on Thursday, May 1st. Morgan Stanley dropped their price objective on Glaukos from $110.00 to $72.00 and set an “underweight” rating on the stock in a research note on Tuesday, May 6th. Finally, William Blair upgraded Glaukos to a “strong-buy” rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Glaukos has an average rating of “Moderate Buy” and a consensus price target of $127.42.
Read Our Latest Stock Analysis on Glaukos
About Glaukos
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Articles
- Five stocks we like better than Glaukos
- Trading Stocks: RSI and Why it’s Useful
- Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4
- Bank Stocks – Best Bank Stocks to Invest In
- Why Datadog Is the AI Infrastructure Firm to Watch Out For
- What Are Earnings Reports?
- 4 Stocks Every AI ETF Is Buying—And They’re Not What You Think
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.